Frazier Life Sciences Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
KCM
BBA
Frazier Life Sciences Management's CLDX Position: Q3 2026 in Review
Frazier Life Sciences Management opened a new position in Celldex Therapeutics (CLDX) in Q3 2026: 900,080 shares worth $29.2M. The stake represents 0.72% of the portfolio and ranks #26 among its holdings.
249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Frazier Life Sciences Management held 900,080 shares of Celldex Therapeutics worth $29.2M as of Q3 2026.
- Celldex Therapeutics was a new Frazier Life Sciences Management position in Q3 2026.
- Celldex Therapeutics made up 0.72% of Frazier Life Sciences Management's portfolio in Q3 2026, its #26 holding.
- 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Frazier Life Sciences Management's 13F filing for Q3 2026, filed 16 Nov 2026.